{
    "id": 32182,
    "fullName": "SDC1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SDC1 positive indicates the presence of the SDC1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6382,
        "geneSymbol": "SDC1",
        "terms": [
            "SDC1",
            "CD138",
            "SDC",
            "SYND1",
            "syndecan"
        ]
    },
    "variant": "positive",
    "createDate": "01/21/2020",
    "updateDate": "01/21/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19919,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Taxol (paclitaxel) and Indatuximab ravtansine (BT062) inhibited tumor growth in a SDC1 (CD138)-expressing triple-negative breast cancer patient-derived xenograft (PDX) model (PMID: 29666962).",
            "molecularProfile": {
                "id": 34692,
                "profileName": "SDC1 positive"
            },
            "therapy": {
                "id": 9254,
                "therapyName": "Indatuximab ravtansine + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17590,
                    "pubMedId": 29666962,
                    "title": "Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29666962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19920,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Indatuximab ravtansine (BT062) and Taxotere (docetaxel) inhibited tumor growth in SDC1 (CD138)-expressing triple-negative breast cancer patient-derived xenograft (PDX) models, and demonstrated increased efficacy over controls in a TNBC PDX model with low SDC1 expression (PMID: 29666962).",
            "molecularProfile": {
                "id": 34692,
                "profileName": "SDC1 positive"
            },
            "therapy": {
                "id": 9255,
                "therapyName": "Docetaxel + Indatuximab ravtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17590,
                    "pubMedId": 29666962,
                    "title": "Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29666962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34692,
            "profileName": "SDC1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}